Brain-Computer Interface Company Synchron Raises $200M
Synchron, a New York-based company specializing in non-surgical brain-computer interface (BCI) technology, announced it has raised $200 million in a Series D funding round. This investment aims to fast-track the commercialization of its first-generation Stentrode BCI platform and accelerate development of an advanced next-generation interface.
Funding Details and Investors
The recent financing brings Synchron’s total funding to $345 million. Double Point Ventures led this round, joined by existing investors including ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS. New participants in this round are the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
About the Stentrode Platform
Synchron’s Stentrode platform is recognized as the first endovascular brain-computer interface, developed to convert brain activity into digital commands without requiring open-brain surgery. The device is implanted through a minimally invasive catheter procedure and interfaces wirelessly with the motor cortex via blood vessels.
“The Stentrode interfaces with the motor cortex through the blood vessels, recording and transmitting neural signals wirelessly to enable hands-free control of digital devices.”
Applications and Impact
- Enables hands-free digital device control by interpreting neural signals.
- Offers a non-surgical alternative to traditional brain-computer interfaces.
- Aims to improve accessibility and ease of use for people with motor impairments.
Author’s summary: Synchron’s $200 million funding accelerates the launch of its pioneering Stentrode brain-computer interface, a minimally invasive device enabling wireless neural control of digital technology.